A comparative study of single-dose treatment of chancroid using thiamphenicol versus Azithromycin

Brazilian Journal of Infectious Diseases

Walter B. Junior²  Nilton G. Di Chiacchio¹  Nilton Di Chiacchio¹  Ricardo Romiti²  Paulo R. Criado¹  Paulo Eduardo N. Ferreira Velho¹ 

[1] ,São Paulo University Department of Dermatology

关键词: Azithromycin;    chancroid;    Haemophilus ducreyi;    single dose;    thiamphenicol;   

DOI  :  10.1590/S1413-86702009000300012

来源: SciELO

【 摘 要 】

A study was conducted in São Paulo, Brazil, to compare azithromycin with thiamphenicol for the single-dose treatment of chancroid. In all, 54 men with chancroid were tested. The etiology was determined by clinical characterization and direct bacterioscopy with Gram staining. None of the patients had positive serology or dark-field examination indicating active infection with Treponema pallidum. Genital infections due to Neisseria gonorrhoeae and herpes simplex virus were excluded by polymerase chain reaction testing. For 54 patients with chancroid, cure rates with single-dose treatment were 73% with azithromycin and 89% with thiamphenicol. HIV seropositivity was found to be associated with treatment failure (p=0.001). The treatment failed in all HIV positive patients treated with azithromycin (p=0.002) and this drug should be avoided in these co-infected patients. In the view of the authors, thiamphenicol is the most indicated single-dose regimen for chancroid treatment.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License